Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 403

1.

Clinical and Laboratory Features of Patients with Acquired Thrombotic Thrombocytopaenic Purpura: Fourteen Years of the Milan TTP Registry.

Mancini I, Pontiggia S, Palla R, Artoni A, Valsecchi C, Ferrari B, Mikovic D, Peyvandi F; Italian Group of TTP Investigators.

Thromb Haemost. 2019 Mar 12. doi: 10.1055/s-0039-1679907. [Epub ahead of print]

PMID:
30861548
2.

Hypercoagulability and the risk of recurrence in young women with myocardial infarction or ischaemic stroke: a cohort study.

Maino A, Algra A, Peyvandi F, Rosendaal FR, Siegerink B.

BMC Cardiovasc Disord. 2019 Mar 7;19(1):55. doi: 10.1186/s12872-019-1040-4.

3.

Complications of whole-exome sequencing for causal gene discovery in primary platelet secretion defects.

Gorski MM, Lecchi A, Femia EA, La Marca S, Cairo A, Pappalardo E, Lotta LA, Artoni A, Peyvandi F.

Haematologica. 2019 Feb 28. pii: haematol.2018.204990. doi: 10.3324/haematol.2018.204990. [Epub ahead of print]

4.

Understanding the Impact of Aberrant Splicing in Coagulation Factor V Deficiency.

Paraboschi EM, Menegatti M, Peyvandi F, Duga S, Asselta R.

Int J Mol Sci. 2019 Feb 20;20(4). pii: E910. doi: 10.3390/ijms20040910.

5.

Risk of diagnostic delay in congenital thrombotic thrombocytopenic purpura.

Ferrari B, Cairo A, Pagliari MT, Mancini I, Arcudi S, Peyvandi F.

J Thromb Haemost. 2019 Feb 14. doi: 10.1111/jth.14409. [Epub ahead of print]

PMID:
30762934
6.

A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.

Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, Federici AB.

Blood Transfus. 2019 Feb 4:1-8. doi: 10.2450/2019.0183-18. [Epub ahead of print]

7.

Role of the factor VIII-binding capacity of endogenous von Willebrand factor on the development of factor VIII inhibitors in patients with severe hemophilia A.

Repessé Y, Costa C, Palla R, Farrokhi Moshai E, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Jan 31. pii: haematol.2018.212001. doi: 10.3324/haematol.2018.212001. [Epub ahead of print]

8.

Body mass index reduction improves the baseline procoagulant imbalance of obese subjects.

Tripodi A, Primignani M, Badiali S, de Ruberto F, Granelli P, Tosetti G, Clerici M, Padovan L, Chantarangkul V, Scalambrino E, Peyvandi F.

J Thromb Thrombolysis. 2019 Jan 30. doi: 10.1007/s11239-019-01818-9. [Epub ahead of print]

PMID:
30701462
9.

Prevention of relapse in patients with acquired thrombotic thrombocytopenic purpura undergoing elective surgery: a case series.

Arcudi S, Ferrari B, Pontiggia S, Tufano A, Artoni A, Mancini I, Peyvandi F.

J Thromb Haemost. 2019 Mar;17(3):492-498. doi: 10.1111/jth.14381. Epub 2019 Feb 25.

PMID:
30629316
10.

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators.

N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.

PMID:
30625070
11.

Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study.

Tripodi A, Chantarangkul V, Clerici M, Bader R, Anzoletti MB, Peyvandi F, Santagostino EM; PredicTGA Collaborators.

Thromb Res. 2019 Feb;174:84-87. doi: 10.1016/j.thromres.2018.12.007. Epub 2018 Dec 6. No abstract available.

PMID:
30579150
12.

Treatment of rare factor deficiencies other than hemophilia.

Menegatti M, Peyvandi F.

Blood. 2019 Jan 31;133(5):415-424. doi: 10.1182/blood-2018-06-820738. Epub 2018 Dec 17. Review.

PMID:
30559262
13.

Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.

Schelpe AS, Roose E, Joly BS, Pareyn I, Mancini I, Biganzoli M, Deckmyn H, Voorberg J, Fijnheer R, Peyvandi F, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.

Haematologica. 2018 Dec 6. pii: haematol.2018.205666. doi: 10.3324/haematol.2018.205666. [Epub ahead of print]

14.

The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.

Oldenburg J, Mahlangu JN, Bujan W, Trask P, Callaghan MU, Young G, Asikanius E, Peyvandi F, Santagostino E, Kruse-Jarres R, Negrier C, Kessler C, Xu J, Windyga J, Shima M, von Mackensen S.

Haemophilia. 2019 Jan;25(1):33-44. doi: 10.1111/hae.13618. Epub 2018 Nov 14.

PMID:
30427582
15.

Thromboelastometry. Reproducibility of duplicate measurement performed by the RoTem® device.

Scalambrino E, Padovan L, Clerici M, Chantarangkul V, Biliou S, Peyvandi F, Tripodi A.

Thromb Res. 2018 Dec;172:139-141. doi: 10.1016/j.thromres.2018.10.030. Epub 2018 Oct 31. No abstract available.

PMID:
30412836
16.

Severe acquired von Willebrand syndrome secondary to systemic lupus erythematosus.

Stufano F, Baronciani L, Biguzzi E, Cozzi G, Colpani P, Chisini M, Peyvandi F.

Haemophilia. 2019 Jan;25(1):e30-e32. doi: 10.1111/hae.13626. Epub 2018 Nov 8. No abstract available.

PMID:
30408840
17.

Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery.

Peyvandi F, Mamaev A, Wang JD, Stasyshyn O, Timofeeva M, Curry N, Cid AR, Yee TT, Kavakli K, Castaman G, Sytkowski A.

J Thromb Haemost. 2019 Jan;17(1):52-62. doi: 10.1111/jth.14313. Epub 2018 Dec 20.

PMID:
30362288
18.

Hemostatic abnormalities in patients with Ehlers-Danlos syndrome.

Artoni A, Bassotti A, Abbattista M, Marinelli B, Lecchi A, Gianniello F, Clerici M, Bucciarelli P, La Marca S, Peyvandi F, Martinelli I.

J Thromb Haemost. 2018 Dec;16(12):2425-2431. doi: 10.1111/jth.14310. Epub 2018 Nov 8.

PMID:
30312027
19.

Advances in the Treatment of Hemophilia: Implications for Laboratory Testing.

Tripodi A, Chantarangkul V, Novembrino C, Peyvandi F.

Clin Chem. 2019 Feb;65(2):254-262. doi: 10.1373/clinchem.2017.284356. Epub 2018 Oct 3. Review.

PMID:
30282700
20.

Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Roose E, Vidarsson G, Kangro K, Verhagen OJHM, Mancini I, Desender L, Pareyn I, Vandeputte N, Vandenbulcke A, Vendramin C, Schelpe AS, Voorberg J, Azerad MA, Gilardin L, Scully M, Dierickx D, Deckmyn H, De Meyer SF, Peyvandi F, Vanhoorelbeke K.

Thromb Haemost. 2018 Oct;118(10):1729-1742. doi: 10.1055/s-0038-1669459. Epub 2018 Sep 20.

21.

Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes.

de Haan HG, van Hylckama Vlieg A, Lotta LA, Gorski MM, Bucciarelli P, Martinelli I, Baglin TP, Peyvandi F, Rosendaal FR; INVENT consortium.

J Thromb Haemost. 2018 Dec;16(12):2432-2441. doi: 10.1111/jth.14279. Epub 2018 Oct 16.

PMID:
30168256
22.

Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls.

Mannucci PM, Nobili A, Marchesini E, Oliovecchio E, Cortesi L, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Peyvandi F, Iorio A.

Haemophilia. 2018 Sep;24(5):726-732. doi: 10.1111/hae.13595. Epub 2018 Aug 16.

PMID:
30112863
23.

Advances in Clinical and Basic Science of Coagulation: Illustrated abstracts of the 9th Chapel Hill Symposium on Hemostasis.

Bergmeier W, Antoniak S, Conway EM, Denis CV, George LA, Isermann B, Key NS, Krishnaswamy S, Lam WA, Lillicrap D, Liu J, Looney MR, López JA, Maas C, Peyvandi F, Ruf W, Sood AK, Versteeg HH, Wolberg AS, Wong PC, Wood JP, Weiler H.

Res Pract Thromb Haemost. 2018 Apr 12;2(3):407-428. doi: 10.1002/rth2.12095. eCollection 2018 Jul. Review.

24.

Product type and other environmental risk factors for inhibitor development in severe hemophilia A.

Peyvandi F, Garagiola I.

Res Pract Thromb Haemost. 2018 Apr 10;2(2):220-227. doi: 10.1002/rth2.12094. eCollection 2018 Apr.

25.

Differential diagnosis between type 2A and 2B von Willebrand disease in a child with a previously undescribed de novo mutation.

Pagliari MT, Baronciani L, Stufano F, Colpani P, Siboni SM, Peyvandi F.

Haemophilia. 2018 Jul;24(4):e263-e266. doi: 10.1111/hae.13532. Epub 2018 Jul 25. No abstract available.

PMID:
30044032
26.

Next-generation DNA sequencing to identify novel genetic risk factors for cerebral vein thrombosis.

Gorski MM, de Haan HG, Mancini I, Lotta LA, Bucciarelli P, Passamonti SM, Cairo A, Pappalardo E, van Hylckama Vlieg A, Martinelli I, Rosendaal FR, Peyvandi F.

Thromb Res. 2018 Sep;169:76-81. doi: 10.1016/j.thromres.2018.06.011. Epub 2018 Jun 15.

PMID:
30029070
27.

How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues.

Tripodi A, Braham S, Scimeca B, Moia M, Peyvandi F.

Pol Arch Intern Med. 2018 Jun 29;128(6):379-385. doi: 10.20452/pamw.4287. Epub 2018 Jun 29.

28.

Evaluation of the Utility of von Willebrand Factor Propeptide in the Differential Diagnosis of von Willebrand Disease and Acquired von Willebrand Syndrome.

Stufano F, Boscarino M, Bucciarelli P, Baronciani L, Maino A, Cozzi G, Peyvandi F.

Semin Thromb Hemost. 2019 Feb;45(1):36-42. doi: 10.1055/s-0038-1660481. Epub 2018 Jun 18.

PMID:
29913537
29.

An international collaborative study to compare different von Willebrand factor glycoprotein Ib binding activity assays: the COMPASS-VWF study.

Szederjesi A, Baronciani L, Budde U, Castaman G, Lawrie AS, Liu Y, Montgomery R, Peyvandi F, Schneppenheim R, Várkonyi A, Patzke J, Bodó I.

J Thromb Haemost. 2018 Jun 13. doi: 10.1111/jth.14206. [Epub ahead of print]

PMID:
29897666
30.

Risk factors for inhibitor development in severe hemophilia a.

Garagiola I, Palla R, Peyvandi F.

Thromb Res. 2018 Aug;168:20-27. doi: 10.1016/j.thromres.2018.05.027. Epub 2018 May 25. Review.

PMID:
29879570
31.

Choices of factor VIII products in previously untreated patients with haemophilia A: A global survey.

Peyvandi F, Palla R, Franchi C, Nobili A, Rosendaal FR, Mannucci PM.

Haemophilia. 2018 Jul;24(4):e266-e268. doi: 10.1111/hae.13535. Epub 2018 Jun 5. No abstract available.

PMID:
29869363
32.

Recombinant factor XIII A-subunit in a patient with factor XIII deficiency and recurrent pregnancy loss.

Al-Khabori M, Pathare A, Menegatti M, Peyvandi F.

J Thromb Haemost. 2018 Jun;16(6):1052-1054. doi: 10.1111/jth.14126. Epub 2018 May 13.

PMID:
29665207
33.

Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards.

Proietti M, Antoniazzi S, Monzani V, Santalucia P, Franchi C; SIM-AF Investigators, Fenoglio LM, Melchio R, Fabris F, Sartori MT, Manfredini R, De Giorgi A, Fabbian F, Biolo G, Zanetti M, Altamura N, Sabbà C, Suppressa P, Bandiera F, Usai C, Murialdo G, Fezza F, Marra A, Castelli F, Cattaneo F, Beccati V, di Minno G, Tufano A, Contaldi P, Lupattelli G, Bianconi V, Cappellini D, Hu C, Minonzio F, Fargion S, Burdick L, Francione P, Peyvandi F, Rossio R, Colombo G, Monzani V, Ceriani G, Lucchi T, Brignolo B, Manfellotto D, Caridi I, Corazza GR, Miceli E, Padula D, Fraternale G, Guasti L, Squizzato A, Maresca A, Liberato NL, Tognin T, Rozzini R, Bellucci FB, Muscaritoli M, Molfino A, Petrillo E, Dore M, Mete F, Gino M, Franceschi F, Gabrielli M, Perticone F, Perticone M, Bertolotti M, Mussi C, Borghi C, Strocchi E, Durazzo M, Fornengo P, Dallegri F, Ottonello LC, Salam K, Caserza L, Barbagallo M, Di Bella G, Annoni G, Bruni AA, Odetti P, Nencioni A, Monacelli F, Napolitano A, Brucato A, Valenti A, Castellino P, Zanoli L, Mazzeo M.

Eur J Intern Med. 2018 Jun;52:e12-e14. doi: 10.1016/j.ejim.2018.04.006. Epub 2018 Apr 12. No abstract available.

PMID:
29657108
34.

"In vitro" correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate.

Bulato C, Novembrino C, Anzoletti MB, Spiezia L, Gavasso S, Berbenni C, Tagariello G, Farina C, Nardini I, Campello E, Peyvandi F, Simioni P.

Haemophilia. 2018 Jul;24(4):648-656. doi: 10.1111/hae.13465. Epub 2018 Mar 26.

PMID:
29578313
35.

An unusual diagnosis in a 31-year-old man with abdominal pain and hyponatremia.

Depetri F, Cugno M, Graziadei G, Di Pierro E, Granata F, Peyvandi F, Cappellini MD.

Intern Emerg Med. 2018 Dec;13(8):1233-1238. doi: 10.1007/s11739-018-1826-x. Epub 2018 Mar 17. No abstract available.

PMID:
29550908
36.

First-year results of an expanded humanitarian aid programme for haemophilia in resource-constrained countries.

Pierce GF, Haffar A, Ampartzidis G, Peyvandi F, Diop S, El-Ekiaby M, van den Berg HM.

Haemophilia. 2018 Mar;24(2):229-235. doi: 10.1111/hae.13409. Epub 2018 Mar 14.

PMID:
29537123
37.

Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban.

Martinelli I, Abbattista M, Bucciarelli P, Tripodi A, Artoni A, Gianniello F, Novembrino C, Peyvandi F.

Haematologica. 2018 Jul;103(7):e315-e317. doi: 10.3324/haematol.2017.185132. Epub 2018 Mar 8. No abstract available.

38.

Acquired thrombotic thrombocytopenic purpura in a child: rituximab to prevent relapse. A pediatric report and literature review.

Mariani S, Trisolini SM, Capria S, Moleti ML, Chisini M, Ferrazza G, Bafti MS, Limongiello MA, Miulli E, Peyvandi F, Foà R, Testi AM.

Haematologica. 2018 Mar;103(3):e138-e140. doi: 10.3324/haematol.2017.185363. No abstract available.

39.

Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.

Spena S, Garagiola I, Cannavò A, Mortarino M, Mannucci PM, Rosendaal FR, Peyvandi F; SIPPET Study Group.

J Thromb Haemost. 2018 Apr;16(4):778-790. doi: 10.1111/jth.13961. Epub 2018 Mar 23.

PMID:
29399993
40.

Further comments on "High-titre inhibitors in previously untreated patients with severe haemophilia A receiving recombinant or plasma-derived factor VIII: a budget-impact analysis".

Messori A, Peyvandi F, Trippoli S, Palla R, Rosendaal FR, Mannucci PM.

Blood Transfus. 2019 Jan;17(1):86. doi: 10.2450/2017.0253-17. Epub 2017 Dec 22. No abstract available.

41.

Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia.

Reda G, Cassin R, Artoni A, Fattizzo B, Lecchi A, La Marca S, Bucciarelli P, Levati GV, Peyvandi F, Cortelezzi A.

Br J Haematol. 2018 Dec;183(5):825-828. doi: 10.1111/bjh.15052. Epub 2018 Jan 7. No abstract available.

PMID:
29315493
42.

Acquired Von Willebrand syndrome and response to desmopressin.

Biguzzi E, Siboni SM, Peyvandi F.

Haemophilia. 2018 Jan;24(1):e25-e28. doi: 10.1111/hae.13382. Epub 2017 Dec 13. No abstract available.

PMID:
29239101
43.

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency.

Ross C, Rangarajan S, Karimi M, Toogeh G, Apte S, Lissitchkov T, Acharya S, Manco-Johnson MJ, Srivastava A, Brand B, Schwartz BA, Knaub S, Peyvandi F.

J Thromb Haemost. 2018 Feb;16(2):253-261. doi: 10.1111/jth.13923. Epub 2018 Jan 22.

44.

Efficacy and safety of a new human fibrinogen concentrate in patients with congenital fibrinogen deficiency: an interim analysis of a Phase III trial.

Lissitchkov T, Madan B, Djambas Khayat C, Zozulya N, Ross C, Karimi M, Kavakli K, De Angulo GR, Almomen A, Schwartz BA, Solomon C, Knaub S, Peyvandi F.

Transfusion. 2018 Feb;58(2):413-422. doi: 10.1111/trf.14421. Epub 2017 Nov 30.

45.

Persistent and severe hypoglycemia associated with trimethoprim-sulfamethoxazole in a frail diabetic man on polypharmacy: A case report and literature review
.

Rossio R, Arcudi S, Peyvandi F, Piconi S.

Int J Clin Pharmacol Ther. 2018 Feb;56(2):86-89. doi: 10.5414/CP203084. Review.

PMID:
29191263
46.

Molecular investigation of 41 patients affected by coagulation factor XI deficiency.

Rimoldi V, Paraboschi EM, Menegatti M, Peyvandi F, Salomon O, Duga S, Asselta R.

Haemophilia. 2018 Mar;24(2):e50-e55. doi: 10.1111/hae.13378. Epub 2017 Nov 27. No abstract available.

PMID:
29178608
47.

Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity.

Donadon I, McVey JH, Garagiola I, Branchini A, Mortarino M, Peyvandi F, Bernardi F, Pinotti M.

Haematologica. 2018 Feb;103(2):344-350. doi: 10.3324/haematol.2017.178327. Epub 2017 Nov 23.

48.

A comparative evaluation of a new fully automated assay for von Willebrand factor collagen binding activity to an established method.

Stufano F, Baronciani L, Mane-Padros D, Cozzi G, Faraudo S, Peyvandi F.

Haemophilia. 2018 Jan;24(1):156-161. doi: 10.1111/hae.13371. Epub 2017 Nov 22.

PMID:
29168270
49.

Platelet to Lymphocyte Ratio and Neutrophil to Lymphocyte Ratio as Risk Factors for Venous Thrombosis.

Artoni A, Abbattista M, Bucciarelli P, Gianniello F, Scalambrino E, Pappalardo E, Peyvandi F, Martinelli I.

Clin Appl Thromb Hemost. 2018 Jul;24(5):808-814. doi: 10.1177/1076029617733039. Epub 2017 Oct 31.

50.

Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.

Peyvandi F, Cannavò A, Garagiola I, Palla R, Mannucci PM, Rosendaal FR; sippet study group.

J Thromb Haemost. 2018 Jan;16(1):39-43. doi: 10.1111/jth.13888. Epub 2017 Nov 16.

Supplemental Content

Loading ...
Support Center